BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 25636507)

  • 21. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
    Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
    Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.
    Li JZ; Wang ZL; Xu WH; Li Q; Gao L; Wang ZM
    Cancer Invest; 2016; 34(4):181-8. PubMed ID: 27031291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
    Li X; Song Y; Zhang P; Zhu H; Chen L; Xiao Y; Xing Y
    Tumour Biol; 2016 Jun; 37(6):7599-613. PubMed ID: 26687646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2E1 changes the biological function of gastric cancer cells via the PI3K/Akt/mTOR signaling pathway.
    Wang RY; Chen XW; Zhang WW; Jiang F; Liu MQ; Shen XB
    Mol Med Rep; 2020 Feb; 21(2):842-850. PubMed ID: 31974627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.
    Vo BT; Morton D; Komaragiri S; Millena AC; Leath C; Khan SA
    Endocrinology; 2013 May; 154(5):1768-79. PubMed ID: 23515290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
    Zhang Y; Cheng H; Li W; Wu H; Yang Y
    Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition.
    Luo W; Tan P; Rodriguez M; He L; Tan K; Zeng L; Siwko S; Liu M
    J Biol Chem; 2017 Sep; 292(37):15525-15537. PubMed ID: 28768769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
    Huang YK; Kang WM; Ma ZQ; Liu YQ; Zhou L; Yu JC
    Carcinogenesis; 2019 Apr; 40(2):370-379. PubMed ID: 30371738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway.
    Yao H; Su S; Xia D; Wang M; Li Z; Chen W; Ren L; Xu L
    Biomed Pharmacother; 2018 Nov; 107():1712-1719. PubMed ID: 30257389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.
    Rho SB; Song YJ; Lim MC; Lee SH; Kim BR; Park SY
    Cell Signal; 2012 Jan; 24(1):131-9. PubMed ID: 21893193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling.
    Liu G; Yuan D; Sun P; Liu W; Wu PF; Liu H; Yu GY
    J Cell Physiol; 2018 Nov; 233(11):8639-8647. PubMed ID: 29904919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
    Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
    J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
    Zhu H; Diao S; Lim V; Hu L; Hu J
    Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
    Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
    Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.